New hope for rare cancers: drug combo trial launches

NCT ID NCT04449549

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 30 times

Summary

This study tests two drugs, nilotinib (a pill) and paclitaxel (given by IV), together in people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the combination can shrink or stop tumor growth. About 82 adults with specific rare cancers like certain ovarian cancers, anal cancer, or Ewing sarcoma will take part. Participants receive the drugs in 28-day cycles and are monitored for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

NEOPLASMS NEOPLASMS